Top of page

Student/Staff Portal
Global Site Navigation

School of Medical and Health Sciences

Local Section Navigation
You are here: Main Content
  • Professor Elin Gray

    Professor Elin Gray

Related Contents

  • See Also
  • Google Scholar profile
    http://scholar.google.com.au/citations?hl=en&user=oy1YyWQAAAAJ
  • Google Scholar profile
  • Scopus
    https://www.scopus.com/authid/detail.uri?authorId=14050086600
  • Scopus
  • Twitter
    https://twitter.com/elinsgrayphd?lang=en
  • Twitter
  • LinkedIn
    https://www.linkedin.com/in/elin-gray-27673556/?originalSubdomain=au
  • LinkedIn

Professor Elin Gray

Professor of Cancer Biology

Staff Member Details
Telephone: +61 8 6304 2756
Mobile: 0406 840 197
Email: e.gray@ecu.edu.au
Campus: Joondalup  
Room: JO17.309  
ORCID iD: https://orcid.org/0000-0002-8613-3570

Elin Gray is a Professor of Cancer Research and Deputy Director of ECU’s Centre for Precision Health.

She holds a Cancer Council of Western Australia Research Fellowship, leads the Melanoma Research Group, and conducts research on the development of liquid biopsies.

Background

Prior to appointment at ECU, Elin worked at the National Institute for Communicable Diseases in South Africa; the Vaccine Research Center at the NIH, USA and the Duke Human Vaccine Institute, Duke University, USA. Elin’s previous research focused in immunology and virology before relocating to Edith Cowan University in 2011.

Professor Gray's current research aims to identify blood biomarkers for diagnosis and prognosis of melanoma and other cancers to guide treatment decisions. Her team utilises and develops novel liquid biopsies through the genetic analysis of circulating tumour cells, circulating tumour DNA and extracellular vesicles, to provide information on the tumour evolution and cancer development. In addition, Elin is interested in identifying mechanisms of drug resistance and developing better treatment strategies. Professor Gray works in close collaboration with leading oncologists, pathologists and industry partners to translate these results into clinical application.

Qualifications

  • Doctor of Philosophy, South Africa, 2008.
  • Master in Biochemistry, Cuba, 2001.
  • Bachelor of Biochemistry, Cuba, 1997.

Research Outputs

2024

Journal Articles

  • Denisenko, E., De Kock, L., Tan, A., Beasley, A., Beilin, M., Jones, M., Hou, R., Muirí, D., Bilic, S., Mohan, G., Salfinger, S., Fox, S., Hmon, K., Yeow, Y., Kim, Y., John, R., Gilderman, T., Killingbeck, E., Gray, E., Cohen, P., Yu, Y., Forrest, A. (2024). Spatial transcriptomics reveals discrete tumour microenvironments and autocrine loops within ovarian cancer subclones. Nature Communications, 15(1), Article number 2860. https://doi.org/10.1038/s41467-024-47271-y.
  • Kim, JS., Taaffe, D., Galvao, D., Clay, T., Redfern, AD., Gray, E., Newton, R. (2024). Enhancing circulatory myokines and extracellular vesicle uptake with targeted exercise in patients with prostate cancer (the MYEX trial): a single-group crossover study. BMC Cancer, 24(1), article number 784. https://doi.org/10.1186/s12885-024-12530-0.
  • Acheampong, E., Allsopp, R., Page, K., Wadsley, M., Beasley, A., Coombes, RC., Shaw, J., Gray, E. (2024). Meta-Analysis of Circulating Tumor Cell PD-L1 Expression and the Association with Clinical Outcomes in Non-Small Cell Lung Cancer. Clinical Chemistry (Washington, DC): international journal of molecular diagnostics and laboratory medicine, 70(1), 234-249. https://doi.org/10.1093/clinchem/hvad187.
  • Abed, A., Reid, A., Law, N., Millward, M., Gray, E. (2024). HLA-A01 and HLA-B27 Supertypes, but Not HLA Homozygocity, Correlate with Clinical Outcome among Patients with Non-Small Cell Lung Cancer Treated with Pembrolizumab in Combination with Chemotherapy. Cancers, 16(17), Article number 3102. https://doi.org/10.3390/cancers16173102.

2023

Book Chapters

  • Vasantharajan, SS., Barnett, E., Gray, E., Rodger, E., Eccles, M., Pattison, S., Munro, F., Chatterjee, A. (2023). Size-Based Method for Enrichment of Circulating Tumor Cells from Blood of Colorectal Cancer Patients. Oral Biology: Molecular Techniques and Applications (231-248). Humana Press. https://doi.org/10.1007/978-1-0716-2780-8_15.

Journal Articles

  • Crosby, B., Newton, R., Galvao, D., Taaffe, D., Lopez Da Cruz, PL., Meniawy, T., Khattak, A., Lam, W., Gray, E., Singh, F. (2023). Feasibility of supervised telehealth exercise for patients with advanced melanoma receiving checkpoint inhibitor therapy. Cancer Medicine, 12(13), 14694-14706. https://doi.org/https://doi.org/10.1002/cam4.6091.
  • Beasley, A., De Bruyn, D., Beasley, L., Al-Ogaili, Z., Isaacs, T., Bentel, J., Reid, A., Dwarkasing, R., Pereira, M., Khattak, A., Meniawy, T., Millward, M., Brosens, E., De Klein, A., Chen, F., Kiliҫ, E., Gray, E. (2023). Detection of metastases using circulating tumour DNA in uveal melanoma. Journal of Cancer Research and Clinical Oncology, 2023(Article in press), 11 pages. https://doi.org/10.1007/s00432-023-05271-3.
  • Calapre, L., Giardina, T., Beasley, A., Reid, A., Stewart, C., Amanuel, B., Meniawy, T., Gray, E. (2023). Identiication of TP53 mutations in circulating tumour DNA in high grade serous ovarian carcinoma using next generation sequencing technologies. Scientific Reports, 13(1), Article number 278. https://doi.org/10.1038/s41598-023-27445-2.
  • Abed, A., Beasley, A., Reid, A., Law, N., Beasley, L., Millward, M., Lo, J., Gray, E. (2023). Circulating pre-treatment T-cell receptor repertoire as a predictive biomarker in advanced or metastatic non-small-cell lung cancer patients treated with pembrolizumab alone or in combination with chemotherapy. ESMO Open, 8(6), Article number 102066. https://doi.org/10.1016/j.esmoop.2023.102066.
  • Warburton, L., Reid, A., Amanuel, B., Beasley, L., Millward, M., Gray, E. (2023). Detectable ctDNA at the time of treatment cessation of ipilimumab and nivolumab for toxicity predicts disease progression in advanced melanoma patients. Frontiers in Oncology, 13(Article in press), Article number 1280730. https://doi.org/10.3389/fonc.2023.1280730.
  • Carlessi, R., Denisenko, E., Boslem, E., Köhn-Gaone, J., Main, N., Abu Bakar, ND., Shirolkar, G., Jones, M., Beasley, A., Poppe, D., Dwyer, B., Jackaman, C., Tjiam, M., Lister, R., Karin, M., Fallowfield, J., Kendall, T., Forbes, S., Gray, E., Olynyk, J., Yeoh, G., Forrest, A., Ramm, G., Febbraio, M., Tirnitz-Parker, J. (2023). Single-nucleus RNA sequencing of pre-malignant liver reveals disease-associated hepatocyte state with HCC prognostic potential. Cell Genomics, 3(5), Article number 100301. https://doi.org/10.1016/j.xgen.2023.100301.
  • Cohen, R., Beasley, A., McCoy, M., Platell, C., Meehan, K., Gray, E., Fuller, K. (2023). Locally performed postoperative circulating tumour DNA testing performed during routine clinical care to predict recurrence of colorectal cancer. ANZ Journal of Surgery, 2023(Article in press), 8 pages. https://doi.org/10.1111/ans.18385.
  • Beasley, A., Preen, D., McLenachan, S., Gray, E., Chen, F. (2023). Incidence and Mortality of Conjunctival Melanoma in Australia (1982 to 2014). Investigative Ophthalmology and Visual Science, 64(14), Article number 2. https://doi.org/https://doi.org/10.1167/iovs.64.14.2.
  • Acheampong, E., Morici, M., Abed, A., Bowyer, S., Asante, D., Lin, W., Millward, M., Gray, E., Beasley, A. (2023). Powering single-cell genomics to unravel circulating tumour cell subpopulations in non-small cell lung cancer patients. Journal of Cancer Research and Clinical Oncology, 149(5), 1941-1950. https://doi.org/10.1007/s00432-022-04202-y.
  • Asante, D., Mohan, G., Acheampong, E., Ziman, M., Calapre, L., Meniawy, T., Gray, E., Beasley, A. (2023). Genetic analysis of heterogeneous subsets of circulating tumour cells from high grade serous ovarian carcinoma patients. Scientific Reports, 13(1), Article number 2552. https://doi.org/10.1038/s41598-023-29416-z.
  • Taylor, J., Gandhi, A., Gray, E., Zaenker, P. (2023). Checkpoint inhibitor immune-related adverse events: A focused review on autoantibodies and B cells as biomarkers, advancements and future possibilities. Frontiers in Immunology, 13(January 2023), Article number 991433. https://doi.org/10.3389/fimmu.2022.991433.
  • Medhin, L., Beasley, A., Warburton, L., Amanuel, B., Gray, E. (2023). Extracellular vesicles as a liquid biopsy for melanoma: Are we there yet?. Seminars in Cancer Biology, 89(February 2023), 92-98. https://doi.org/10.1016/j.semcancer.2023.01.008.

2022

Journal Articles

  • Acheampong, E., Abed, A., Morici, M., Spencer, I., Beasley, A., Bowyer, S., Asante, D., Lomma, C., Lin, W., Millward, M., Gray, E. (2022). Evaluation of PD-L1 expression on circulating tumour cells in small-cell lung cancer. Translational Lung Cancer Research, 11(5), 440-451. https://doi.org/10.21037/tlcr-21-819.
  • Beasley, A., Chen, F., Isaacs, T., Gray, E. (2022). Future perspectives of uveal melanoma blood based biomarkers. British Journal of Cancer, 126(11), 1511-1528. https://doi.org/10.1038/s41416-022-01723-8.
  • De Bruyn, D., Beasley, A., Verdijk, R., Van Poppelen, N., Paridaens, D., De Keizer, R., Naus, N., Gray, E., De Klein, A., Brosens, E., Kilic, E. (2022). Is tissue still the issue? The promise of liquid biopsy in Uveal Melanoma. Biomedicines, 10(2), Article Number 506. https://doi.org/10.3390/biomedicines10020506.
  • Kim, JS., Taaffe, D., Galvao, D., Hart, N., Gray, E., Ryan, C., Kenfield, S., Saad, F., Newton, R. (2022). Exercise in advanced prostate cancer elevates myokine levels and suppresses in-vitro cell growth. Prostate Cancer and Prostatic Diseases, 25(1), 86-92. https://doi.org/10.1038/s41391-022-00504-x.
  • Kim, JS., Taaffe, D., Galvao, D., Clay, T., Redfern, A., Hart, N., Gray, E., Ryan, C., Kenfield, S., Saad, F., Newton, R. (2022). Acute effect of high-intensity interval aerobic exercise on serum myokine levels and resulting tumour-suppressive effect in trained patients with advanced prostate cancer. Prostate Cancer and Prostatic Diseases, 2022(Article in Press), TBD. https://doi.org/10.1038/s41391-022-00624-4.
  • Oey, O., Liu, Y., Sunjaya, AF., Simadibrata, DM., Khattak, A., Gray, E. (2022). Gut Microbiota Diversity And Composition In Predicting Immunotherapy Response And Immunotherapy-Related Colitis In Melanoma Patients: A Systematic Review. World Journal of Clinical Oncology, 13(11), TBD. https://doi.org/10.5306/wjco.v13.i11.929.
  • Sexauer, D., Gray, E., Zaenker, P. (2022). Tumour-associated Autoantibodies as Prognostic Cancer Biomarkers - A Review. Autoimmunity Reviews, 21(4), Article number 103041. https://doi.org/10.1016/j.autrev.2022.103041.
  • Kim, J., Wilson, R., Taaffe, D., Galvao, D., Gray, E., Newton, R. (2022). Myokine Expression and Tumor-suppressive Effect of Serum following 12 Weeks of Exercise in Prostate Cancer Patients on ADT. Medicine and Science in Sports and Exercise, 54(2), 197-205. https://doi.org/10.1249/MSS.0000000000002783.
  • Marsavela, G., McEvoy, A., Pereira, M., Reid, A., Al-Ogaili, Z., Warburton, L., Khattak, A., Abed, A., Meniawy, T., Millward, M., Ziman, M., Beasley, L., Gray, E. (2022). Detection of clinical progression through plasma ctDNA in metastatic melanoma patients: a comparison to radiological progression. British Journal of Cancer, 126(3), 401-408. https://doi.org/10.1038/s41416-021-01507-6.
  • Dyke, J., Beasley, L., Beasley, A., Gray, E., Allcock, R., Bentel, J. (2022). Application of multiplex ligation-dependent probe amplification (MLPA) and low pass whole genome sequencing (LP-WGS) to the classification / characterisation of low grade glioneuronal tumours. Pathology, Research and Practice, 229(January 2022), Article number 153724. https://doi.org/10.1016/j.prp.2021.153724.
  • Abed, A., Law, N., Beasley, L., Lo, J., Bhat, V., Bowyer, S., Millward, M., Gray, E. (2022). Human leucocyte antigen genotype association with the development of immune-related adverse events in patients with non-small cell lung cancer treated with single agent immunotherapy. European Journal of Cancer, 172(Sept 2022), 98-106. https://doi.org/10.1016/j.ejca.2022.05.021.
  • Scheepers, C., Kgagudi, P., Mzindle, N., Gray, E., Moyo-Gwete, T., Lambson, B., Oosthuysen, B., Mabvakure, B., Garrett, N., Abdool Karim, S., Morris, L., Moore, P. (2022). Dependence on a variable residue limits the breadth of an HIV MPER neutralizing antibody, despite convergent evolution with broadly neutralizing antibodies. PLoS Pathogens, 18(9), Article number e1010450. https://doi.org/10.1371/journal.ppat.1010450.
  • Vasantharajan, S., Barnett, E., Gray, E., McCall, J., Rodger, E., Eccles, M., Munro, F., Pattison, S., Chatterjee, A. (2022). Assessment of a Size-Based Method for Enriching Circulating Tumour Cells in Colorectal Cancer. Cancers, 14(14), Article number 3446. https://doi.org/10.3390/cancers14143446.

2021

Book Chapters

  • Beasley, A., Acheampong, E., Lin, W., Gray, E. (2021). Multi-marker immunomagnetic enrichment of circulating melanoma cells. Melanoma. Methods and Protocols (213-222). Humana Press. https://doi.org/10.1007/978-1-0716-1205-7_16.
  • Morici, M., Lin, W., Gray, E. (2021). Transcript-based detection of circulating melanoma cells. Melanoma. Methods and Protocols (235-245). Humana Press. https://doi.org/10.1007/978-1-0716-1205-7_18.
  • Marsavela, G., Reid, A., Gray, E., Beasley, L. (2021). Isolation and quantification of plasma circulating tumor DNA from melanoma patients. Melanoma. Methods and Protocols (247-263). Humana Press. https://doi.org/10.1007/978-1-0716-1205-7_19.

Journal Articles

  • Scott, J., Johnston, R., Blane, S., Strickland, M., Darby, J., Gray, E. (2021). Investigating primary preservice teachers’ ultraviolet radiation awareness and perceived ability to teach sun safety. Health Promotion Journal of Australia, 32(S2), 178-184. https://doi.org/10.1002/hpja.401.
  • Mavropalias, G., Beasley, L., Morici, M., Koeda, T., Poon, W., Barley, O., Gray, E., Blazevich, T., Nosaka, K. (2021). Changes in plasma hydroxyproline and plasma cell‑free DNA concentrations after higher‑ versus lower‑intensity eccentric cycling. European Journal of Applied Physiology, 121(4), 1087-1097. https://doi.org/10.1007/s00421-020-04593-1.
  • Beasley, A., Preen, DB., McLenachan, S., Gray, E., Chen, FK. (2021). Incidence and mortality of uveal melanoma in Australia (1982–2014). British Journal of Ophthalmology, 2021(Article in press), 1-6. https://doi.org/10.1136/bjophthalmol-2021-319700.
  • Tangella, P., Clark, M., Gray, E. (2021). Resistance mechanisms to targeted therapy in BRAF-mutant melanoma - A mini review. Biochimica et Biophysica Acta (BBA): General Subjects, 1865(1), Article number 129736. https://doi.org/10.1016/j.bbagen.2020.129736.
  • Lin, W., Beasley, A., Ardakani, N., Denisenko, E., Beasley, L., Jones, M., Wood, B., Warburton, L., Forrest, A., Gray, E. (2021). Intra- and inter-tumoral heterogeneity of liver metastases in a patient with uveal melanoma revealed by single-cell RNA sequencing. Cold Spring Harbor Molecular Case Studies, 7(5), article number a006111. https://doi.org/10.1101/mcs.a006111.
  • Park, J., Diefenbach, R., Byrne, N., Long, G., Scolyer, R., Gray, E., Carlino, M., Rizos, H. (2021). Circulating tumor DNA reflects uveal melanoma responses to protein Kinase C inhibition. Cancers, 13(7), Article number1740. https://doi.org/10.3390/cancers13071740.
  • Asante, D., Morici, M., Mohan, G., Acheampong, E., Spencer, I., Lin, W., Van Miert, P., Gibson, S., Beasley, A., Ziman, M., Beasley, L., Meniawy, T., Gray, E. (2021). Multi-Marker Immunofluorescent Staining and PD-L1 Detection on Circulating Tumour Cells from Ovarian Cancer Patients. Cancers, 13(24), Article number 6225. https://doi.org/10.3390/cancers13246225.
  • Crosby, B., Lopez Da Cruz, P., Galvao, D., Newton, R., Taaffe, D., Meniawy, T., Warburton, L., Khattak, A., Gray, E., Singh, F. (2021). Associations of Physical Activity and Exercise with Health-related Outcomes in Patients with Melanoma During and After Treatment: A Systematic Review. Integrative Cancer Therapies, 20(January-December 2021), Article Number: 15347354211040757. https://doi.org/10.1177/15347354211040757.
  • Beasley, A., Isaacs, T., Vermeulen, T., Freeman, J., Desousa, J., Bhikoo, R., Hennessy, D., Reid, A., Chen, F., Bentel, J., McKay, D., Conway, R., Pereira, M., Mirzai, B., Beasley, L., Erber, W., Ziman, M., Gray, E. (2021). Analysis of Circulating Tumour Cells in Early-Stage Uveal Melanoma: Evaluation of Tumour Marker Expression to Increase Capture. Cancers, 13(23), Article 5990. https://doi.org/10.3390/cancers13235990.
  • Kim, J., Galvao, D., Newton, R., Gray, E., Taaffe, D. (2021). Exercise-induced myokines and their effect on prostate cancer. Nature Reviews Urology, 18(9), 519-542. https://doi.org/10.1038/s41585-021-00476-y.
  • Scott, J., Johnston, R., Bear, N., Gregory, S., Blane, S., Strickland, M., Darby, J., Gray, E. (2021). Targeted Teacher Education to Improve Primary Preservice Teachers’ Knowledge and Understanding of UV and Effective Sun Protection Measures for Children. Australian Journal of Teacher Education, 46(3), 53-73. https://doi.org/10.14221/ajte.2021v46n3.4.
  • Tangella, P., Arooj, M., Deplazes, E., Gray, E., Mancera, R. (2021). Identification and characterisation of putative drug binding sites in human ATP-binding cassette B5 (ABCB5) transporter. Computational and Structural Biotechnology Journal, 19(2021), 691-704. https://doi.org/10.1016/j.csbj.2020.12.042.
  • Vasantharajan, S., Eccles, M., Rodger, E., Pattison, S., McCall, J., Gray, E., Beasley, L., Chatterjee, A. (2021). The epigenetic landscape of circulating tumour cells. Biochimica et Biophysica Acta: Reviews on Cancer, 1875(2), Article number 188514. https://doi.org/10.1016/j.bbcan.2021.188514.

2020

Journal Articles

  • Goonoo, N., Boodhun, A., Ziman, M., Gray, E., Bhaw-Luximon, A. (2020). Repurposing nano-enabled polymeric scaffolds for tumor-wound management and 3D tumor engineering. Regenerative Medicine, 15(10), 2229-2247. https://doi.org/10.2217/rme-2020-0072.
  • Warburton, L., Beasley, L., Pereira, M., Reid, A., Robinson, C., Amanuel, B., Ziman, M., Millward, M., Gray, E. (2020). Circulating Tumour DNA in Advanced Melanoma Patients Ceasing PD1 Inhibition in the Absence of Disease Progression. Cancers, 12(11), Article number 3486. https://doi.org/10.3390/cancers12113486.
  • Warburton, L., Meniawy, T., Beasley, L., Pereira, M., McEvoy, A., Ziman, M., Gray, E., Millward, M. (2020). Stopping targeted therapy for complete responders in advanced BRAF mutant melanoma. Scientific Reports, 10(1), Article number 18878. https://doi.org/10.1038/s41598-020-75837-5.
  • Marsavela, G., Johansson, P., Pereira, M., McEvoy, A., Reid, A., Robinson, C., Warburton, L., Khattak, A., Meniawy, T., Amanuel, B., Millward, M., Hayward, N., Ziman, M., Gray, E., Beasley, L. (2020). The Prognostic Impact of Circulating Tumour DNA in Melanoma Patients Treated with Systemic Therapies-Beyond BRAF Mutant Detection. Cancers, 12(12), Article number 3793. https://doi.org/10.3390/cancers12123793.
  • Beasley, A., Bentel, J., Allcock, R., Vermeulen, T., Beasley, L., Isaacs, T., Ziman, M., Chen, F., Gray, E. (2020). Low-Pass Whole-Genome Sequencing as a Method of Determining Copy Number Variations in Uveal Melanoma Tissue Samples. The Journal of Molecular Diagnostics, 22(3), 429-434. https://doi.org/10.1016/j.jmoldx.2019.12.005.
  • Abed, A., Beasley, L., Lo, J., Correia, S., Bowyer, S., Chopra, A., Watson, M., Khattak, A., Millward, M., Gray, E. (2020). Prognostic value of HLA-I homozygosity in patients with non-small cell lung cancer treated with single agent immunotherapy. Journal for ImmunoTherapy of Cancer, 8(2), Article number e001620. https://doi.org/10.1136/jitc-2020-001620.
  • Nguyen, B., Meehan, K., Pereira, M., Mirzai, B., Lim, SH., Leslie, C., Clark, M., Sader, C., Friedland, P., Lindsay, A., Tang, C., Millward, M., Gray, E., Lim, A. (2020). A comparative study of extracellular vesicle-associated and cell-free DNA and RNA for HPV detection in oropharyngeal squamous cell carcinoma. Scientific Reports, 10(December 2020), Article number 6083. https://doi.org/10.1038/s41598-020-63180-8.
  • Aya-Bonilla, C., Morici, M., Hong, X., McEvoy, A., Sullivan, R., Freeman, J., Beasley, L., Khattak, A., Meniawy, T., Millward, M., Ziman, M., Gray, E. (2020). Detection and prognostic role of heterogeneous populations of melanoma circulating tumour cells. British Journal of Cancer, 122(7), 1059-1067. https://doi.org/10.1038/s41416-020-0750-9.
  • Marsavela, G., Lee, J., Beasley, L., Wong, S., Pereira, M., McEvoy, A., Reid, A., Robinson, C., Warburton, L., Abed, A., Khattak, A., Meniawy, T., Dawson, S., Sandhu, S., Carlino, M., Menzies, A., Scolyer, R., Long, G., Amanuel, B., Millward, M., Ziman, M., Rizos, H., Gray, E. (2020). Circulating Tumor DNA Predicts Outcome from First-, but not Second-line Treatment and Identifies Melanoma Patients Who May Benefit from Combination Immunotherapy. Clinical Cancer Research, 26(22), 5926-5933. https://doi.org/10.1158/1078-0432.CCR-20-2251.
  • Clark, M., Rizos, H., Pereira, M., McEvoy, A., Marsavela, G., Beasley, L., Meehan, K., Ruhen, O., Khattak, A., Meniawy, T., Long, G., Carlino, M., Menzies, A., Millward, M., Ziman, M., Gray, E. (2020). Detection of BRAF splicing variants in plasma-derived cell-free nucleic acids and extracellular vesicles of melanoma patients failing targeted therapy therapies. Oncotarget, 11(44), 4016-4027. https://doi.org/10.18632/oncotarget.27790.
  • Acheampong, E., Abed, A., Morici, M., Bowyer, S., Amanuel, B., Lin, W., Millward, M., Gray, E. (2020). Tumour PD-L1 Expression in Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis. Cells, 9(11), Article Number 2393. https://doi.org/10.3390/cells9112393.
  • Asante, D., Beasley, L., Ziman, M., Meniawy, T., Gray, E. (2020). Liquid biopsy in ovarian cancer using circulating tumor DNA and cells: Ready for prime time?. Cancer Letters, 468(1 January 2020), 59-71. https://doi.org/10.1016/j.canlet.2019.10.014.
  • Johansson, P., Brooks, K., Newell, F., Palmer, J., Wilmott, J., Pritchard, A., Broit, N., Wood, S., Carlino, M., Leonard, C., Koufariotis, L., Nathan, V., Beasley, A., Howlie, M., Dawson, R., Rizos, H., Schmidt, C., Long, G., Hamilton, H., Kiilgaard, J., Isaacs, T., Gray, E., Rolfe, O., Park, J., Stark, A., Mann, G., Scolyer, R., Pearson, J., Van Baren, N., Waddell, N., Wadt, K., McGrath, L., Warrier, S., Glasson, W., Hayward, N. (2020). Whole genome landscapes of uveal melanoma show an ultraviolet radiation signature in iris tumours. Nature Communications, 11(1), Article number 2408. https://doi.org/10.1038/s41467-020-16276-8.
  • Khattak, A., Reid, A., Freeman, J., Pereira, M., McEvoy, A., Lo, J., Frank, M., Meniawy, T., Didan, A., Spencer, I., Amanuel, B., Millward, M., Ziman, M., Gray, E. (2020). PD-L1 Expression on Circulating Tumor Cells May Be Predictive of Response to Pembrolizumab in Advanced Melanoma: Results from a Pilot Study. The Oncologist, 25(3), e520-e527. https://doi.org/10.1634/theoncologist.2019-0557.
  • Khattak, A., Abed, A., Reid, A., McEvoy, A., Millward, M., Ziman, M., Gray, E. (2020). Role of Serum Vascular Endothelial Growth Factor (VEGF) as a Potential Biomarker of Response to Immune Checkpoint Inhibitor Therapy in Advanced Melanoma: Results of a Pilot Study. Frontiers in Oncology, 10(30 June 2020), Article number 1041. https://doi.org/10.3389/fonc.2020.01041.
  • Lee, J., Menzies, A., Carlino, M., McEvoy, A., Sandhu, S., Weppler, A., Diefenbach, R., Dawson, S., Kefford, R., Millward, M., Al-Ogaili, Z., Tra, T., Gray, E., Wong, S., Scolyer, R., Long, G., Rizos, H. (2020). Longitudinal monitoring of ctDNA in patients with melanoma and brain metastases treated with immune checkpoint inhibitors. Clinical Cancer Research, 26(15), 4064-4071. https://doi.org/10.1158/1078-0432.CCR-19-3926.

2019

Journal Articles

  • Stark, M., Gray, E., Isaacs, T., Chen, F., Millward, M., McEvoy, A., Zaenker, P., Ziman, M., Soyer, H., Glasson, W., Warrier, S., Stark, A., Rolfe, O., Palmer, J., Hayward, N. (2019). A Panel of Circulating MicroRNAs Detects Uveal Melanoma With High Precision. Translational Vision Science and Technology, 8(6), Article 12. https://doi.org/10.1167/tvst.8.6.12.
  • Acheampong, E., Spencer, I., Lin, W., Ziman, M., Millward, M., Gray, E. (2019). Is the Blood an Alternative for Programmed Cell Death Ligand 1 Assessment in Non-Small Cell Lung Cancer?. Cancers, 11(7), article no. 920. https://doi.org/10.3390/cancers11070920.
  • Beasley, L., Giardina, T., Robinson, C., Reid, A., Al-Ogaili, Z., Pereira, M., McEvoy, A., Warburton, L., Hayward, N., Khattak, A., Meniawy, T., Millward, M., Amanuel, B., Ziman, M., Gray, E. (2019). Locus-specific concordance of genomic alterations between tissue and plasma circulating tumor DNA in metastatic melanoma. Molecular Oncology, 13(2), 171-184. https://doi.org/10.1002/1878-0261.12391.
  • Beasley, L., Warburton, L., Millward, M., Gray, E. (2019). Circulating tumour DNA (ctDNA) as a biomarker in metachronous melanoma and colorectal cancer- a case report. BMC Cancer, 19(1), Article number 1109. https://doi.org/10.1186/s12885-019-6336-3.
  • Armitage, J., Tan, D., Cha, L., Clark, M., Gray, E., Fuller, K., Moodley, Y. (2019). A standardised protocol for the evaluation of small extracellular vesicles in plasma by imaging flow cytometry. Journal of Immunological Methods, 468(May 2019), 61-66. https://doi.org/10.1016/j.jim.2019.03.006.
  • McEvoy, A., Pereira, M., Reid, A., Pearce, R., Cowell, L., Al-Ogaili, Z., Khattak, A., Millward, M., Meniawy, T., Gray, E., Ziman, M. (2019). Monitoring melanoma recurrence with circulating tumor DNA: a proof of concept from three case studies. Oncotarget, 10(2), 113-122. https://doi.org/10.18632/oncotarget.26451.
  • Aya-Bonilla, C., Gray, E., Manikandan, J., Freeman, J., Zaenker, P., Reid, A., Khattak, M., Frank, M., Millward, M., Ziman, M. (2019). Immunomagnetic-Enriched Subpopulations of Melanoma Circulating Tumour Cells (CTCs) Exhibit Distinct Transcriptome Profiles. Cancers, 11(2), Article number 157. https://doi.org/10.3390/cancers11020157.
  • Gray, E., Witkowski, T., Pereira, M., Beasley, L., Herron, K., Irwin, D., Chapman, B., Khattak, A., Raleigh, J., Hatzimihalis, A., Cebon, J., Sandhu, S., McArthur, G., Millward, M., Ziman, M., Dubrovic, A., Wong, S. (2019). Genomic Analysis of Circulating Tumor DNA Using a Melanoma-Specific UltraSEEK Oncogene Panel. The Journal of Molecular Diagnostics, 21(3), 418-426. https://doi.org/10.1016/j.jmoldx.2018.12.001.

2018

Journal Articles

  • Zaenker, P., Lo, J., Pearce, R., Cantwell, P., Cowell, L., Lee, M., Quirk, C., Law, H., Gray, E., Ziman, M. (2018). A diagnostic autoantibody signature for primary cutaneous melanoma. Oncotarget, 9(55), 30539-30551. https://doi.org/10.18632/oncotarget.25669.
  • McEvoy, A., Wood, B., Ardakani, N., Pereira, M., Pearce, R., Cowell, L., Robinson, C., Grieu-Iacopetta, F., Spicer, A., Amanuel, B., Ziman, M., Gray, E. (2018). Droplet Digital PCR for Mutation Detection in Formalin-Fixed, Paraffin-Embedded Melanoma Tissues: A Comparison with Sanger Sequencing and Pyrosequencing. The Journal of Molecular Diagnostics, 20(2), 240-252. https://doi.org/10.1016/j.jmoldx.2017.11.009.
  • Marsavela, G., Aya-Bonilla, C., Warkiani, M., Gray, E., Ziman, M. (2018). Melanoma circulating tumor cells: Benefits and challenges required for clinical application. Cancer Letters, 424(Jun 2018), 1-8. https://doi.org/10.1016/j.canlet.2018.03.013.
  • Dunkel, Y., Reid, A., Ear, J., Aznar, N., Millward, M., Gray, E., Pearce, R., Ziman, M., Ghosh, P. (2018). Prognostic relevance of CCDC88C (Daple) transcripts in the peripheral blood of patients with cutaneous melanoma. Scientific Reports, 8(1), Article number 18036. https://doi.org/10.1038/s41598-018-36173-x.
  • McEvoy, A., Warburton, L., Al-Ogaili, Z., Celliers, L., Beasley, L., Pereira, M., Khattak, A., Meniawy, T., Millward, M., Ziman, M., Gray, E. (2018). Correlation between circulating tumour DNA and metabolic tumour burden in metastatic melanoma patients. BMC Cancer, 18(1), Article no. 726. https://doi.org/10.1186/s12885-018-4637-6.
  • Beasley, A., Isaacs, T., Khattak, A., Freeman, J., Allcock, R., Chen, F., Pereira, M., Yau, K., Bentel, J., Vermeulen, T., Beasley, L., Millward, M., Ziman, M., Gray, E. (2018). Clinical Application of Circulating Tumor Cells and Circulating Tumor DNA in Uveal Melanoma. JCO Precision Oncology, 2(May 17, 2018), 12p.. https://doi.org/10.1200/PO.17.00279.

2017

Journal Articles

  • Beasley, L., Gray, E., Kurdykowski, S., David, A., Descargues, P., Ziman, M. (2017). SIRT1 activation mediates heat-induced survival of UVB damaged Keratinocytes. BMC Dermatology, 17(June 2017), Article No. 8. https://doi.org/10.1186/s12895-017-0060-y.
  • Khattak, A., Gray, E. (2017). Ipilimumab Activity in Advanced Uveal Melanoma: A Pooled Analysis. International Journal of Cancer and Clinical Research, 4(2), article no.088. https://doi.org/10.23937/2378-3419/1410088.
  • McEvoy, A., Beasley, L., Pereira, M., Giardina, T., Robinson, C., Khattak, M., Meniawy, T., Pritchard, A., Hayward, N., Amanuel, B., Millward, M., Ziman, M., Gray, E. (2017). Sensitive droplet digital PCR method for detection of TERT promoter mutations in cell free DNA from patients with metastatic melanoma. Oncotarget, 8(45), 78890-78900. https://doi.org/10.18632/oncotarget.20354.
  • Beasley, L., Warburton, L., Millward, M., Ziman, M., Gray, E. (2017). Circulating tumour DNA (ctDNA) as a liquid biopsy for melanoma. Cancer Letters, 404(28 Sept, 2017), 62-69. https://doi.org/10.1016/j.canlet.2017.06.030.
  • Aya-Bonilla, C., Marsavela, G., Freeman, J., Lomma, C., Frank, M., Khattak, M., Tarek, M., Millward, M., Warkiani, M., Gray, E., Ziman, M. (2017). Isolation and detection of circulating tumour cells from metastatic melanoma patients using a slanted spiral microfluidic device. Oncotarget, 8(40), 67355-67368. https://doi.org/10.18632/oncotarget.18641.

2016

Journal Articles

  • Mufhandu, HT., Alexandre, KB., Gray, E., Morris, L., Khati, M. (2016). UCLA1 aptamer inhibition of human immunodeficiency virus type 1 subtype C primary isolates in macrophages and selection of resistance. Biochemistry and Biophysics Reports, 7(1), 408-414. https://doi.org/10.1016/j.bbrep.2016.07.005.
  • Beasley, L., Gray, E., Kurdykowski, S., David, A., Hart, P., Descargues, P., Ziman, M. (2016). Heat-mediated reduction of apoptosis in UVB-damaged keratinocytes in vitro and in human skin ex vivo. BMC Dermatology, 16(1), Article no. 6. https://doi.org/10.1186/s12895-016-0043-4.
  • Bradley, T., Trama, A., Tumba, N., Gray, E., Lu, X., Madani, N., Jahanbakhsh, F., Eaton, A., Xia, S., Parks, R., Lloyd, KE., Sutherland, LL., Scearce, RM., Bowman, CM., Barnett, SW., Abdool-Karim, SS., Boyd, SD., Melillo, BN., Smith III, AB., Sodroski, JG., Kepler, TB., Alam, SM., Gao, F., Bonsignori, M., Liao, H., Moody, MA., Montefiori, DC., Santra, S., Morris, L., Haynes, BF. (2016). Amino Acid Changes in the HIV-1 gp41 Membrane Proximal Region Control Virus Neutralization Sensitivity. EBioMedicine, 12(October), 196-207. https://doi.org/10.1016/j.ebiom.2016.08.045.
  • Zaenker, P., Gray, E., Ziman, M. (2016). Autoantibody Production in Cancer—The Humoral Immune Response toward Autologous Antigens in Cancer Patients. Autoimmunity Reviews, 15(5), 477-483. https://doi.org/10.1016/j.autrev.2016.01.017.

2015

Book Chapters

Journal Articles

  • Gray, E., Reid, A., Bowyer, S., Beasley, L., Siew, K., Pearce, R., Cowell, L., Frank, M., Millward, M., Ziman, M. (2015). Circulating Melanoma Cell Subpopulations: Their Heterogeneity and Differential Responses to Treatment. Journal of Investigative Dermatology, 135(8), 2040-2048. https://doi.org/10.1038/jid.2015.127.
  • Reid, A., Freeman, J., Millward, M., Ziman, M., Gray, E. (2015). Detection of BRAF-V600E and V600K in melanoma circulating tumour cells by droplet digital PCR. Clinical Biochemistry, 48(15), 999-1002. https://doi.org/10.1016/j.clinbiochem.2014.12.007.
  • Gray, E., Rizos, H., Reid, A., Boyd, S., Pereira, M., Lo, J., Tembe, V., Freeman, J., Lee, J., Scolyer, R., Siew, K., Lomma, C., Cooper, A., Khattak, M., Meniawy, T., Long, G., Carlino, M., Millward, M., Ziman, M. (2015). Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma. Oncotarget, 6(39), 42008-42018. https://doi.org/10.18632/oncotarget.5788.
  • Richardson, S., Gray, E., Mkhize, N., Sheward, D., Lambson, B., Wibmer, CK., Masson, L., Werner, L., Garrett, N., Passmore, J., Abdool Karim, Q., Abdool Karim, S., Williamson, C., Moore, P., Morris, L. (2015). South African HIV-1 subtype C transmitted variants with a specific V2 motif show higher dependence on aα4β7 for replication. Retrovirology, 12(54), Article Number 54. https://doi.org/10.1186/s12977-015-0183-3.
  • Bandawe, G., Moore, P., Werner, L., Gray, E., Sheward, D., Madiga, M., Nofemela, A., Thebus, R., Marais, J., Maboko, L., Karim, S., Hoelscher, M., Morris, L., Williamson, C. (2015). Differences in HIV type 1 neutralization breadth in 2 geographically distinct cohorts in Africa. Journal of Infectious Diseases, 211(9), 1461-1466. https://doi.org/10.1093/infdis/jiu633.
  • Moody, A., Gao, F., Gurley, T., Amos, J., Kumar, A., Hora, B., Marshall, D., Whitesides, J., Xia, S., Parks, R., Lloyd, K., Hwang, K., Lu, X., Bonsignori, M., Finzi, A., Vandergrift, N., Alam, M., Ferrari, G., Shen, X., Tomaras, G., Kamanga, G., Cohen, M., Sam, N., Kapiga, S., Gray, E., Tumba, N., Morris, L., Zolla-Pazner, S., Gorny, M., Mascola, J., Hahn, B., Shaw, G., Sodroski, J., Liao, H., Montefiori, D., Hraber, P., Korber, B., Haynes, B. (2015). Strain-Specific V3 and CD4 Binding Site Autologous HIV-1 Neutralizing Antibodies Select Neutralization-Resistant Viruses. Cell Host and Microbe, 18(3), 354-362. https://doi.org/10.1016/j.chom.2015.08.006.

Conference Publications

  • Maurya, D., Fooladvand, M., Gray, E., Ziman, M., Alameh, K. (2015). Lab-on-chip platform for circulating tumor cells isolation. Micro+Nano Materials, Devices, and Systems (9668-34). SPIE. https://doi.org/10.1117/12.2201127.

2014

Journal Articles

  • Klinac, D., Gray, E., Freeman, J., Reid, A., Bowyer, S., Millward, M., Ziman, M. (2014). Monitoring changes in circulating tumour cells as a prognostic indicator of overall survival and treatment response in patients with metastatic melanoma. BMC Cancer, 14(1), Article number 423. https://doi.org/10.1186/1471-2407-14-423.

2013

Journal Articles

  • Klinac, D., Gray, E., Milward, M., Ziman, M. (2013). Advances in personalized targeted treatment of metastatic melanoma and non-invasive tumor monitoring. Frontiers in Oncology, 3(March 2013), Article 00054. https://doi.org/10.3389/fonc.2013.00054.
  • Alexandre, K., Moore, P., Nonyane, M., Gray, E., Ranchobe, N., Chakauya, E., McMahon, J., O'Keefe, B., Chikwamba, R., Morris, L. (2013). Mechanisms of HIV-1 subtype C resistance to GRFT, CV-N and SVN. Virology, 446(1-2), 66-76. https://doi.org/10.1016/j.virol.2013.07.019.
  • Beasley, L., Gray, E., Ziman, M. (2013). Heat stress: a risk factor for skin carcinogenesis. Cancer Letters, 337(1), 35-40. https://doi.org/10.1016/j.canlet.2013.05.039.
  • Wibmer, C., Bhiman, J., Gray, E., Tumba, N., Abdool Karim, SS., Williamson, C., Morris, L., Moore, P. (2013). Viral Escape from HIV-1 Neutralizing Antibodies Drives Increased Plasma Neutralization Breadth through Sequential Recognition of Multiple Epitopes and Immunotypes. PLoS Pathogens, 9(10), 16p.. https://doi.org/10.1371/journal.ppat.1003738.
  • Moore, PL., Sheward, D., Nonyane, M., Ranchobe, N., Hermanus, T., Gray, E., Karim, SS., Williamson, C., Morris, L. (2013). Multiple pathways of escape from HIV broadly cross-neutralizing V2-dependent antibodies. Journal of Virology, 87(9), 4882-4894. https://doi.org/10.1128/JVI.03424-12.
  • Lacerda, M., Moore, P., Ngandu, N., Seaman, M., Gray, E., Murrell, B., Krishnamoorthy, M., Nonyane, M., Madiga, M., Wibmer, C., Sheward, D., Bailer, R., Gao, H., Greene, K., Karim, S., Mascola, J., Korber, B., Montefiori, D., Morris, L., Williamson, C., Seoighe, C. (2013). Identification of broadly neutralizing antibody epitopes in the HIV-1 envelope glycoprotein using evolutionary models. Virology Journal, 10(Article no. 347), 18 p.. https://doi.org/10.1186/1743-422X-10-347.

2012

Journal Articles

  • Lynch, R., Tran, L., Louder, M., Schmidt, S., Cohen, M., Dersimonian, R., Euler, Z., Gray, E., Karim, S., Kirchherr, J., Montefiori, D., Sibeko, S., Soderberg, K., Tomaras, G., Yang, Z., Nabel, G., Schultemaker, H., Morris, L., Haynes, B., Mascola, J. (2012). The Development of CD4 Binding Site Antibodies during HIV-1 Infection. Journal of Virology, 86(14), 7588-7595. https://doi.org/10.1128/JVI.00734-12.
  • Freeman, J., Gray, E., Milward, M., Pearce, R., Ziman, M. (2012). Evaluation of a multi-marker immunomagnetic enrichment assay for the quantification of circulating melanoma cells. Journal of Translational Medicine, 10(1), art. no. 192. https://doi.org/10.1186/1479-5876-10-192.
  • Mufhandu, H., Gray, E., Madiga, M., Tumba, N., Alexandre, K., Khoza, T., Wibmer, C., Moore, P., Morris, L., Khati, M. (2012). UCLA1, a synthetic derivative of a gp120 RNA aptamer, inhibits entry of human immunodeficiency virus type 1 subtype C. Journal of Virology, 86(9), 4989-4999. https://doi.org/10.1128/JVI.06893-11.
  • Archary, D., Rong, R., Gordon, M., Boliar, S., Madiga, M., Gray, E., Dugast, A., Hermanus, T., Goulder, P., Coovadia, H., Werner, L., Morris, L., Alter, G., Derdeyn, C., Ndung'u, T. (2012). Characterization of anti-HIV-1 neutralizing and binding antibodies in chronic HIV-1 subtype C infection. Virology, 433(2), 410-420. https://doi.org/10.1016/j.virol.2012.08.033.
  • Alexandre, K., Gray, E., Mufhandu, H., McMahon, J., Chakauya, E., O'Keefe, B., Chikwamba, R., Morris, L. (2012). The lectins griffithsin, cyanovirin-N and scytovirin inhibit HIV-1 binding to the DC-SIGN receptor and transfer to CD4+ cells. Virology, 423(2), 175-186. https://doi.org/10.1016/j.virol.2011.12.001.
  • Moore, P., Gray, E., Wibmer, CK., Bhiman, J., Nonyane, M., Sheward, D., Hermanus, T., Bajimaya, S., Tumba, N., Abrahams, M., Lambson, B., Ranchobe, N., Ping, L., Ngandu, N., Karim, Q., Karim, S., Swanstrom, R., Seaman, M., Williamson, C., Morris, L. (2012). Evolution of an HIV glycan–dependent broadly neutralizing antibody epitope through immune escape. Nature Medicine, 18(11), 1688-1692. https://doi.org/10.1038/nm.2985.

2011

Journal Articles

  • Alexandre, K., Gray, E., Pantophlet, R., Moore, P., McMahon, J., Chakauya, E., O'Keefe, B., Chikwamba, R., Morris, L. (2011). Binding of the mannose-specific lectin, Griffithsin, to HIV-1 gp120 exposes the CD4-binding site. Journal of Virology, 85(17), 9039-9050. https://doi.org/10.1128/JVI.02675-10.
  • Moore, P., Gray, E., Sheward, D., Madiga, M., Ranchobe, N., Lai, Z., Honnen, W., Nonyane, M., Tumba, N., Hermanus, T., Sibeko, S., Mlisana, K., Karim, S., Williamson, C., Pinter, A., Morris, L. (2011). Potent and broad neutralization of HIV-1 subtype C by plasma antibodies targeting a quaternary epitope including residues in the V2 loop. Journal of Virology, 85(7), 3128-3141. https://doi.org/10.1128/JVI.02658-10.
  • Bonsignori, M., Hwang, K., Chen, X., Tsao, C., Morris, L., Gray, E., Marshall, D., Crump, J., Kapiga, S., Sam, N., Sinangil, F., Pancera, M., Yongping, Y., Zhang, B., Zhu, J., Kwong, P., O'Dell, S., Mascola, J., Wu, L., Nabel, G., Phogat, S., Seaman, M., Whitesides, J., Moody, M., Kelsoe, G., Yang, X., Sodroski, J., Shaw, G., Montefiori, D., Kepler, T., Tomaras, G., Alam, S., Liao, H., Haynes, B. (2011). Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors. Journal of Virology, 85(19), 9998-10009. https://doi.org/10.1128/JVI.05045-11.
  • Gray, E., Madiga, M., Hermanus, T., Moore, P., Wibmer, C., Tumba, N., Werner, L., Mlisana, K., Sibeko, S., Williamson, C., Karim, S., Morris, L. (2011). The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4 T cell decline and high viral load during acute infection. Journal of Virology, 85(10), 4828-4840. https://doi.org/10.1128/JVI.00198-11.
  • Tomaras, G., Binley, J., Gray, E., Crooks, E., Osawa, K., Moore, P., Tumba, N., Tong, T., Shen, X., Yates, N., Decker, J., Wibmer, C., Gao, F., Alam, S., Easterbrook, P., Karim, S., Kamanga, G., Crump, J., Cohen, M., Shaw, G., Mascola, J., Haynes, B., Motefiori, D. (2011). Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals. Journal of Virology, 85(21), 11502-11519. https://doi.org/10.1128/JVI.05363-11.
  • Gray, E., Moody, A., Wibmer, C., Chen, X., Marshall, D., Amos, J., Moore, P., Foulger, A., Yu, J., Lambson, B., Karim, S., Whitesides, J., Tomaras, G., Haynes, B., Morris, L., Liao, H. (2011). Isolation of a monoclonal antibody that targets the alpha-2 helix of gp120 and represents the initial autologous neutralizing-antibody response in an HIV-1 subtype C-infected individual. Journal of Virology, 85(15), 7719-7729. https://doi.org/10.1128/JVI.00563-11.
  • Morris, L., Chen, X., Alam, M., Tomaras, G., Zhang, R., Marshall, D., Chen, B., Parks, R., Foulger, A., Jaeger, F., Donathan, M., Bilska, M., Gray, E., Karim, S., Kepler, T., Whitesides, J., Montefiori, D., Moody, MA., Liao, H., Haynes, B. (2011). Isolation of a human anti-HIV gp41 membrane proximal region neutralizing antibody by antigen-specific single B cell sorting. PLoS One, 6(9), Article no. e23532. https://doi.org/10.1371/journal.pone.0023532.

Research Projects

  • Western Australia Melanoma Initiative (WAMI): developing novel treatments for immunotherapy-resistant melanoma, Cancer Research Trust, The Grant, 2024 ‑ 2029, $1,167,284.
  • ctDNA-guided clinical management of melanoma, National Health and Medical Research Council, MRFF - Genomics Health Futures Mission, 2025 ‑ 2029, $923,738.
  • Integrated Multimodal Precision Liquid biopsy to Enhance MElanoma and NSCLC Treatment (IMPLEMENT), National Health and Medical Research Council, MRFF - Genomics Health Futures Mission, 2021 ‑ 2026, $400,000.
  • Enabling Advanced Single Cell Cancer Genomics in Western Australia, Cancer Research Trust, The Grant, 2017 ‑ 2026, $615,245.
  • Enhancing circulatory myokines and extracellular vesicle uptake with targeted exercise in patients with Prostate Cancer: The MYEX Trial, World Cancer Research Fund, Pilot Grants, 2023 ‑ 2026, $117,156.
  • Biomarkers for clinical outcome among patients with advanced or metastatic NSCLC treated with immunotherapy alone or in combination with chemotherapy., International Association for the Study of Lung Cancer, Grant, 2024 ‑ 2025, $73,910.
  • Multimodal Precision Liquid Biopsy to predict the risk of Melanoma Recurrence, US Department of Defense, Melanoma Research Program Team Science Award, 2022 ‑ 2025, $269,326.
  • Predicting prognosis using circulating tumour DNA in uveal melanoma, Cancer Council of WA Inc, Suzanne Cavanagh Early Career Investigator Grants, 2023 ‑ 2025, $35,000.
  • Establishing a Pipeline for Analysing and Visualising Longitudinal TCR Data in a Late-stage Melanoma Patients , Cancer Council of WA Inc, Student Vacation Research Scholarship, 2025, $3,000.
  • Cancer Blood Biomarkers Study, Department of Health WA, Future Health Research & Innovation Fund - Western Australia Cohort Studies - Operational Support Program, 2023 ‑ 2025, $222,384.
  • Multimodal Liquid biopsy to Predict Response of Melanoma to Immuno-Oncology, Spinnaker Health Research Foundation, Janine Chalwell Gift Grant, 2022 ‑ 2024, $102,459.
  • Cancer Blood Biomarkers Study - Biobank, Department of Health WA, Future Health Research and Innovation Fund - Biobank Interim Support Program 2021, 2021 ‑ 2023, $52,000.
  • Developing a blood test for predicting the response to treatment with immunotherapies in melanoma patients, Cancer Council of WA Inc, Grant, 2022 ‑ 2023, $96,453.
  • Identification of melanoma-specific signature that can predict response to immunotherapies., Cancer Council of WA Inc, Suzanne Cavanagh Early Career Investigator Grants, 2021 ‑ 2023, $34,960.
  • TCR repertoire in combination with HLA and TMB as predictor of response to immune checkpoint blockade in melanoma and lung cancer, Thermo Fisher Scientific Australia Pty Ltd, Grant, 2022 ‑ 2023, $200,000.
  • Exploring therapeutic targets for the treatment of metastatic uveal melanoma, Cancer Council of WA Inc, Collaborative Cancer Grant Scheme, 2021 ‑ 2022, $64,718.
  • Medical and Health Research Infrastructure Fund (MHRIF) 2021, Department of Health WA, Medical and Health Research Infrastructure, 2021 ‑ 2022, $47,190.
  • Developing blood tests to guide treatment of melanoma, Cancer Council of WA Inc, Fellowship, 2019 ‑ 2022, $955,724.
  • Circulating Melanoma Cells as Predictive Biomarkers of Response to Immune Checkpoint Blockade , Cancer Council of WA Inc, Grant, 2020 ‑ 2022, $100,000.
  • Liquid Biopsy to assess microscopic residual disease in melanoma, National Health and Medical Research Council, Scholarship, 2020 ‑ 2022, $87,182.
  • Autoantibodies as Biomarkers of Onset of Immune-related Adverse Events in Cutaneous Melanoma Patients, Department of Health WA, Cancer and Palliative Care Network (WACPCN) Cancer Fellowship, 2021 ‑ 2022, $206,812.
  • Genomic HLA heterozygosity, T-cell receptor (TCR) – repertoire diversity and tumor PD-L1 expression as predictive biomarkers of response to immunotherapy in lung cancer patients, Lung Foundation Australia, Ellen Yates Memorial Grant in Aid, 2020 ‑ 2021, $20,000.
  • AMRF Early Career Researcher Grants Program, Australian Melanoma Research Foundation, 2020 Research Grant, 2020 ‑ 2021, $30,000.
  • Circulating tumour DNA as a biomarker of treatment response for patients with advanced high grade serous ovarian cancer receiving neoadjuvant chemotherapy with and without durvalumab and tremilimumab as part of the iprime study, Australia New Zealand Gynaecological Oncology Group (ANZGOG), Grant, 2020 ‑ 2021, $49,317.
  • Medical and Health Research Infrastructure Fund 2019 (Round 23), Department of Health WA, Medical and Health Research Infrastructure, 2020 ‑ 2021, $20,011.
  • Early detection of uveal melanoma, Australian Melanoma Research Foundation, 2020 Research Grant, 2020, $8,500.
  • Early Detection of Cancer Spread and Treatment of Ocular Melanoma, Cancer Council of WA Inc, PhD Top Up Scholarship, 2018 ‑ 2020, $30,000.
  • Liquid biopsy for personalised monitoring of melanoma patients , National Health and Medical Research Council, Development Grants, 2017 ‑ 2020, $820,889.
  • Medical and Health Research Infrastructure Fund 2018 (Round 22), Department of Health WA, Medical and Health Research Infrastructure, 2019 ‑ 2020, $20,979.
  • Translation of "Liquid Biopsy" Research into Clinical Practice, Western Australian Health Translation Network (WAHTN), Western Australian Health Translation Network, 2019 ‑ 2020, $121,074.
  • Single Cell Whole Transcriptome Sequencing of Melanoma Circulating Tumour Cells (CTCs): Unveiling Cell Diversity, Tour de Cure, Pioneering Cancer Research Grant, 2019, $120,000.
  • Predictive significance of circulating tumour cells (CTCs), circulating tumour DNA (ctDNA) and serum vascular endothelial growth factor (VEGF) in advanced melanoma patients treated with pembrolizumab, Merck Sharp and Dohme (Australia) Pty Ltd, Grant, 2016 ‑ 2019, $73,300.
  • Characterisation of Melanoma Circulating Tumour Cells for Personalised Treatment, Cancer Research Trust, Postdoctoral Fellowship, 2014 ‑ 2019, $980,000.
  • Development of a Multiplex Test for the Early Diagnosis of Melanoma, Tour de Cure, Senior Research Grant, 2019, $280,000.
  • Medical and Health Infrastructure Fund award 2016 Round 20, Department of Health WA, Medical and Health Research Infrastructure, 2017 ‑ 2018, $19,463.
  • Blood Based Biomarkers Predictive of Treatment Response in Melanoma, Cancer Council of WA Inc, Grant, 2016 ‑ 2018, $246,822.
  • Genetic Analysis of Blood Markers for Prognosis in Patients with Uveal Melanoma, University of Western Australia, Raine Foundation Grant, 2016 ‑ 2018, $100,000.
  • Circulating Tumour DNA to Predict and Monitor Treatment Response and Detect Acquired Resistance in Patients with Metastatic Melanoma, Ramaciotti Foundation, Grant, 2015 ‑ 2018, $99,911.
  • NHMRC Fellowship 'near-miss' funding, Department of Health WA, Near Miss Merit Awards, 2016 ‑ 2018, $50,000.
  • A Blood Based ‘Liquid Biopsy’ to Improve Healthcare for Metastatic Melanoma Patients, Department of Health WA, SHRAC Research Translation Projects, 2016 ‑ 2018, $218,693.
  • Understanding the Role of Melanoma Exosomes in Intercellular Communication, Cancer Council of WA Inc, Collaborative Cancer Grant Scheme, 2017 ‑ 2018, $43,230.
  • Blood based biomarkers predictive of treatment efficacy in metastatic melanoma, Spinnaker Health Research Foundation, Collaborative Research Partnership Grants, 2017 ‑ 2018, $107,448.
  • Liquid Biopsy for Prognosis of Uveal Melanoma, The Ophthalmic Research Institute of Australia, ORIA - Grant, 2018, $27,551.
  • Gene expression profiling of circulating tumour cells (CTCs) isolated from metastatic melanoma patients using a microfluidic chip, Cancer Council of WA Inc, Grant - Early Career Investigator, 2016 ‑ 2017, $35,000.
  • New Independent Research Infrastructure Support Award 2016, Department of Health WA, New Independent Researcher Infrastructure Support (NIRIS) Awards, 2016 ‑ 2017, $10,000.
  • Circulating Melanoma Cells as Predictive Biomarkers of Treatment Response and Disease Status, Cancer Council of WA Inc, Grant, 2015 ‑ 2017, $111,519.
  • Using a Functional Protein Array to Identify Autoantibody Biomarkers with Diagnostic Potential for Melanoma, National Health and Medical Research Council, Development Grants, 2014 ‑ 2017, $452,058.
  • Western Australia Single-Cell Isolation and Genomics Preparation Facility, Australian Research Council, Grant - Linkage (Infrastructure), 2017, $430,000.
  • Circulating Tumour Cells (CTCs) as a diagnostic tool to monitor disease progression in melanoma patients, Edith Cowan University, ECU Industry Collaboration Grant - 2015 (Round 1), 2015 ‑ 2016, $25,000.
  • Mass Cytometry: A breakthrough in multidimensional systems biology, Australian Research Council, Grant - Linkage (Infrastructure), 2015 ‑ 2016, $1,081,489.
  • Transcriptomic profiling of Circulating Tumour Cells (CTCs) isolated from metastatic melanoma patients, Edith Cowan University, School of Medical and Health Sciences Research Grant Scheme 2016, 2016, $10,000.
  • A Single-Molecule Super-Resolution Microscopy Facility in Western Australia, Australian Research Council, Grant - Linkage (Infrastructure), 2016, $1,600,000.
  • Melanoma Mutation Profiling For Personalised Treatment, National Health and Medical Research Council, Project Grants, 2013 ‑ 2016, $765,359.
  • Genetic Analysis of Melanoma Cells in Blood For Personalised Treatment Management, Edith Cowan University, ECU Early Career Researcher Grant - 2013, 2013 ‑ 2014, $24,083.
  • Detection of Vemurafenib Resistance in Circulating Tumour Cells for Personalised Treatment of Melanoma, Harry Perkins Institute of Medical Research, Scott Kirkbride Melanoma Research Centre - Discovery Research Priming Grant, 2013 ‑ 2014, $68,182.
  • Detection of stem cell markers expression in circulating melanoma cells using multiparameter flow cytometry as a prognosis tool, Edith Cowan University, ECU Early Career Researcher Grant - 2012 (Round 1), 2012 ‑ 2013, $19,480.
  • Expanding Capacity and Capability in Western Australian Flow Cytometry for Earth, Oceans, Environmental and Biomedical Science: State-of-the-Art Four Laser and 12 Colour Analysis, Australian Research Council, Grant - Linkage (Infrastructure), 2012 ‑ 2013, $295,000.
  • Neon Transfection System and Biomedical Research Grade -30oC Freezer for Alzheimer’s and Melanoma Research, National Health and Medical Research Council, Equipment Grant 2011, 2011 ‑ 2012, $10,927.

Research Student Supervision

Current Supervisions

Principal Supervisor

  • Doctor of Philosophy, Interrogating the biomarker potential of methylated cell-free DNA in melanoma patients
  • Doctor of Philosophy, Efficacy of exosome derived from 3D printing stem cell combines with hydrogel to promote neural repair after traumatic brain injury
  • Doctor of Philosophy, Extracellular vesicles as tumour-specific biomarkers of melanoma and lung cancer
  • Doctor of Philosophy, Exploring the Molecular Mechanism of Ferroptosis in Bladder Cancer
  • Doctor of Philosophy, Role of CD44 in metastatic Uveal Melanoma
  • Doctor of Philosophy, Investigating the biological factors influencing the release of circulating tumour DNA
  • Doctor of Philosophy, Liquid Biopsy to assess microscopic residual disease in Melanoma

Associate Supervisor

  • Master of Medical and Health Science by Research, Comparison of Autoantibodies with Circulating-Tumour DNA to Predict and Monitor Clinical Response to Pembrolizumab in Late-Stage Melanoma Patients
  • Master of Medical and Health Science by Research, TCR Repertoire and HLA Genotype as Response Biomarkers to Immune Checkpoint Blockade in Advanced Melanoma Patients
  • Doctor of Philosophy, A multi-omic approach for the detection of melanoma brain metastasis

Completed Supervisions

Principal Supervisor

  • Doctor of Philosophy, Assessment of the clinical utility of ctDNA analysis for melanoma management
  • Doctor of Philosophy, Development and evaluation of methodologies for analysis of CTC and ctDNA in patients with ovarian carcinoma
  • Doctor of Philosophy, Genomic HLA and pre-treatment TCR repertoire as non-invasive biomarkers of clinical outcome to immunotherapy in advanced non-small cell lung cancer patients
  • Master of Science (Human Biology), Genetic markers in circulating tumour cells as a measure of the metastatic propensity of uveal melanoma
  • Doctor of Philosophy, Development of Novel Tests to Improve the Management of Uveal Melanoma
  • Doctor of Philosophy, Unravelling the potential applications of extracellular vesicles for the clinical management of melanoma patients
  • Doctor of Philosophy, An investigation on role of the ATP-binding cassette B5 (ABCB5) transporter as potential mediator of melanoma resistance to BRAF inhibition
  • Doctor of Philosophy, Blood Based Biomarkers of Response to Immunotherapy in Advanced Melanoma
  • Master of Medical and Health Science by Research, Thyroid hormone receptor beta is an oncogene in triple negative subtype of breast cancer
  • Master of Science (Medical Science), Characterizing PD-L1 expression in circulating melanoma and non-small cell lung cancer cells
  • Doctor of Philosophy, Medulloblastoma: New animal models, preclinical drug testing and characterising immune infiltrates
  • Doctor of Philosophy, Assessment of circulating tumour cells in lung cancer patients

Co-principal Supervisor

  • Master of Medical and Health Science by Research, Autoantibodies as prognostic biomarkers for cutaeous melanoma

Associate Supervisor

  • Doctor of Philosophy, The Effects of Exercise on Serum Level Myokines in Prostate Cancer Patients and Suppression of Prostate Cancer Cells Induced by Alteration of Systemic Milieu
  • Master of Medical and Health Science by Research, Exercise as an adjunct therapy in melanoma patients undergoing checkpoint inhibitor therapy
  • Master of Science (Human Biology), Optimisation of the isolation and identification of circulating melanoma cells
  • Doctor of Philosophy, The identification and validation of a diagnostic signature of tumour-associated autoantibodies for the early diagnosis of cutaneous melanoma
  • Doctor of Philosophy, Circulating tumour DNA: A non-invasive biomarker for melanoma
  • Doctor of Philosophy, Heat stress: A risk factor for skin carcinogenesis
Skip to top of page